nicotinic


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to nicotinic: nicotinic acid

nic·o·tin·ic

 (nĭk′ə-tĭn′ĭk, -tē′nĭk)
adj.
1. Of or relating to nicotine.
2. Of or relating to niacin.

nic•o•tin•ic

(ˌnɪk əˈtɪn ɪk, -ˈti nɪk)

adj.
1. of, pertaining to, or containing nicotine.
2. related to or imitating the effects of nicotine.
[1870–75]
Translations

nicotinic

[ˌnikəˈtɪnɪk] ADJ nicotinic acidácido m nicotínico
References in periodicals archive ?
LAHORE -- Qaneta Irfan, a student of the Chemistry Department of the Lahore College for Women University (LCWU), has made a herbal tea using Moringa Oleifera leaves.The leaves of Moringa Oleifera are rich in minerals like beta-carotene of Vitamin A; Vitamin B such as folic acid, pyridoxine and nicotinic acid; vitamin C; D and E.
Presently, the product is in phase two trial to treat agitation and is a negative allosteric modulator of the alpha-7 (alpha-7) nicotinic acetylcholine receptor.
Nicotinic acetylcholine receptors, or nAChR, associated with acetylcholine-mediated neurotransmission have been linked to several neurological conditions and public health issues, notably tobacco addiction.
The study reveals that exercise during nicotine exposure markedly reduces the severity of nicotine withdrawal symptoms, an effect that is accompanied by increased activation of a7 nicotinic acetylcholine receptors (which are targets of nicotine) in the hippocampal region of the brain.
Vitamin [B.sub.3] occurs naturally in two forms: niacin (also called nicotinic acid) and niacinamide (also called nicotinamide).
Some authors have reported that nAChRs stimulation of the brain dopamine receptor system normalizes a number of sensory processing deficits associated with schizophrenia, including sensory, PPI and eye- tracking deficits, the hypothesis of nAChR "hypofunction" in schizophrenia has stimulated the development of selective nicotinic receptor agonists as putative treatments for negative symptoms and cognitive dysfunction.
We provide evidence that the effect of CCL3 is mediated via CCR1 and calcium-independent phospholipase A2 (iPLA2), release of a soluble small mediator and nicotinic acetylcholine receptors (nAChR) containing subunits a7 and a9.
It is characterized by decrease in the number of available nicotinic acetylcholine receptors at postsynaptic membrane due to presence of pathogenic autoantibodies [1, 2].
The protein, called alpha-4-beta-2 nicotinic receptor, sits on nerve cells in the brain.
Patients exhibit muscarinic and nicotinic symptoms depending upon severity of compounds.